Moleculin Biotech, Inc. Cash and Restricted Cash
Moleculin Biotech, Inc. (MBRX) had Cash and Restricted Cash of $7.26 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.26M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.32M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.88M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.70M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $7.26M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $10.32M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $8.88M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $6.70M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $7.56M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $7.72M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $4.28M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $9.40M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $10.85M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $16.82M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $23.55M 10-K · filed 2026-03-18 |
| 2023-09-30 | $24.58M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $32.17M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $37.27M 10-Q · filed 2024-05-10 |
| 2022-12-31 | $43.15M 10-K · filed 2025-03-21 |
| 2022-09-30 | $50.39M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $58.00M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $66.10M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $70.90M 10-K · filed 2024-03-22 |
| 2021-09-30 | $75.18M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $79.51M 10-Q · filed 2022-08-12 |
| 2021-03-31 | $86.29M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $15.17M 10-K · filed 2023-03-22 |
| 2020-09-30 | $12.79M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $16.73M 10-Q · filed 2021-08-11 |
| 2020-03-31 | $11.65M 10-Q · filed 2021-05-12 |
| 2019-12-31 | $10.73M 10-K · filed 2022-03-24 |
| 2019-09-30 | $15.41M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $18.70M 10-Q · filed 2020-08-12 |
| 2019-03-31 | $8.78M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $7.13M 10-K · filed 2021-03-24 |
| 2018-09-30 | $8.60M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $11.72M 10-Q · filed 2019-08-16 |
| 2018-03-31 | $13.11M 10-Q · filed 2019-05-13 |
| 2017-12-31 | $7.71M 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |